close

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The company's product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect company's focus on therapeutics for reproductive disorders. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	3.89
Volume	33124
Volume Avg	92060
52 Week High	6.74
52 Week Low	3.34
PE	N/A
PE (group average)	39
EPS Year	-0.98
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-43.48%
EPS change Q/Q next Q est	-35%
EPS change Y/Y	-1084.75%
REV change Q/Q	200%
REV change Q/Q Yr ago	-40%
EPS next Q est	-0.20
EPS next Y est	-0.61
Divident Annual	0.00
Dividend Yield	0%